Literature DB >> 30761472

Evidence of Significant Ceftriaxone and Quinolone Resistance in Cirrhotics with Spontaneous Bacterial Peritonitis.

Eric Ardolino1, Susan S Wang2, Vilas R Patwardhan3.   

Abstract

OBJECTIVES: There are few studies addressing the impact of cephalosporin and quinolone resistance on hospital length of stay and mortality in spontaneous bacterial peritonitis (SBP). We aim to describe the shifting epidemiology of SBP at our institution and its impact on clinical outcomes.
METHODS: We performed a single-center retrospective cohort study of all cases of SBP from 2005 to 2015 at a transplant center. Cases were identified using hospital billing data. Patient data were confirmed using the electronic medical record. Univariate and multivariate logistic regression and Cox proportional hazards models were used to identify factors that were associated with prolonged hospital length of stay and reduced survival. Culture-positive cases (N = 56) were compared to culture-negative cases (N = 104). Subpopulation analysis of the culture-positive cases compared ceftriaxone-resistant (N = 25) to ceftriaxone-susceptible (N = 31) cases.
RESULTS: We identified 160 cases of SBP (56 culture positive and 104 culture negative; 21 nosocomial, 79 hospital associated, and 60 community acquired). Forty-five percent (N = 25 total, 13 hospital associated and 6 nosocomial) of bacterial isolates were resistant to ceftriaxone, with 37.5% (N = 21) being gram positive, including 8 methicillin-resistant staphylococcus and 6 vancomycin-resistant enterococcus. Multivariate analysis identified hospital-associated SBP, age, alcoholic cirrhosis, and MELD-Na score as variables associated with worse survival (P < 0.05), with a trend toward worse survival in culture-positive cases (P = 0.123). Only MELD-Na was associated with prolonged length of stay.
CONCLUSIONS: The burden of resistant pathogens causing SBP is significant, notably in hospital-associated SBP. Culture-positive SBP may represent a higher risk group compared to culture-negative SBP.

Entities:  

Keywords:  Cephalosporin resistance; Cirrhosis; Quinolone resistance; SBP; Spontaneous bacterial peritonitis

Mesh:

Substances:

Year:  2019        PMID: 30761472     DOI: 10.1007/s10620-019-05519-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

Review 1.  Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis.

Authors:  Marco Fiore; Ivan Gentile; Alberto E Maraolo; Sebastiano Leone; Vittorio Simeon; Paolo Chiodini; Maria C Pace; Thierry Gustot; Fabio S Taccone
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-03       Impact factor: 2.566

2.  Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA.

Authors:  Amelia K Sofjan; Rachel J Musgrove; Nicholas D Beyda; Hannah P Russo; Todd M Lasco; Raymond Yau; Alejandro Restrepo; Kevin W Garey
Journal:  J Glob Antimicrob Resist       Date:  2018-05-26       Impact factor: 4.035

3.  Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites.

Authors:  Luke T Evans; W Ray Kim; John J Poterucha; Patrick S Kamath
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  AlexVianeyCallado França; Helena Maria Giordano; Tiago Sevá-Pereira; Elza Cotrim Soares
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

5.  Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study.

Authors:  A Rimola; J M Salmerón; G Clemente; L Rodrigo; A Obrador; M L Miranda; C Guarner; R Planas; R Solá; V Vargas
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

6.  Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients.

Authors:  Mevlut Baskol; Sebnem Gursoy; Gulden Baskol; Omer Ozbakir; Kadri Guven; Mehmet Yucesoy
Journal:  J Clin Gastroenterol       Date:  2003 Nov-Dec       Impact factor: 3.062

7.  Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia.

Authors:  Alexandra Alexopoulou; Larisa Vasilieva; Danai Agiasotelli; Kyriaki Siranidi; Sophia Pouriki; Athanasia Tsiriga; Marina Toutouza; Spyridon P Dourakis
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

8.  Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections.

Authors:  J Felisart; A Rimola; V Arroyo; R M Perez-Ayuso; E Quintero; P Gines; J Rodes
Journal:  Hepatology       Date:  1985 May-Jun       Impact factor: 17.425

9.  Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

Authors:  Rajiv Jalan; Javier Fernandez; Reiner Wiest; Bernd Schnabl; Richard Moreau; Paolo Angeli; Vanessa Stadlbauer; Thierry Gustot; Mauro Bernardi; Rafael Canton; Agustin Albillos; Frank Lammert; Alexander Wilmer; Rajeshwar Mookerjee; Jordi Vila; Rita Garcia-Martinez; Julia Wendon; José Such; Juan Cordoba; Arun Sanyal; Guadalupe Garcia-Tsao; Vicente Arroyo; Andrew Burroughs; Pere Ginès
Journal:  J Hepatol       Date:  2014-02-12       Impact factor: 25.083

10.  Predictors of fifty days in-hospital mortality in patients with culture negative neutrocytic ascites.

Authors:  Chinmaya Kumar Bal; Vikram Bhatia; Ripu Daman
Journal:  BMC Gastroenterol       Date:  2017-05-16       Impact factor: 3.067

View more
  3 in total

Review 1.  Current Status and Prospects of Spontaneous Peritonitis in Patients with Cirrhosis.

Authors:  Yong-Tao Li; Jian-Rong Huang; Mei-Lian Peng
Journal:  Biomed Res Int       Date:  2020-07-06       Impact factor: 3.411

2.  Spontaneous bacterial peritonitis: a prospective Greek multicenter study of its epidemiology, microbiology, and outcomes.

Authors:  Dimitrios N Samonakis; Nikolaos Gatselis; Aristea Bellou; Dimitra Sifaki-Pistolla; Maria Mela; George Demetriou; Evangelos Thalassinos; Eirini I Rigopoulou; Polyxeni Kevrekidou; Ioannis Tziortziotis; Kalliopi Azariadi; Melina Kavousanaki; Emmanuel Digenakis; Themistoklis Vassiliadis; Elias A Kouroumalis; George N Dalekos
Journal:  Ann Gastroenterol       Date:  2021-11-10

3.  A dual-caged resorufin probe for rapid screening of infections resistant to lactam antibiotics.

Authors:  Jinghang Xie; Ran Mu; Mingxi Fang; Yunfeng Cheng; Fiona Senchyna; Angel Moreno; Niaz Banaei; Jianghong Rao
Journal:  Chem Sci       Date:  2021-05-28       Impact factor: 9.825

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.